A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug

References

• GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioral, environmental, occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1659–1724.
   PubMed Web of Science ®Google Scholar
• Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment of 14-effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36:1637–1647.
   PubMedGoogle Scholar
• Will JC, Zhang Z, Ritchie MD, et al. Medication adherence and incident preventable hospitalizations for hypertension. Am J Prev Med. 2016;50:489–499.
   PubMed Web of Science ®Google Scholar
• Ataabadi EA, Golshiri K, Juttner A, et al. Nitric oxide-cGMP signaling in hypertension. Current and future options for pharmacotherapy. Hypertension. 2020;76(4):1055–1068. .
   PubMed Web of Science ®Google Scholar
• Azizi M, Rossignl P, Hulot JS. Emerging drug classes and their potential use in hypertension. Hypertension. 2019;74:1075–1083.
   PubMed Web of Science ®Google Scholar
• Sandner P. From molecules to patients exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;27:679–690.
   Google Scholar
• Chrysant SG, Chrysant GS. New and Emerging cardiovascular and antihypertensive drugs. Exp Opin Drug Saf. 2020;19(10):1315–1327.
   PubMed Web of Science ®Google Scholar
• Derbyshire ER, Marletta MA, Tobin JV, et al. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81(1):533–539.
   PubMedGoogle Scholar
• Follman M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (Bay 1021 189) for the treatment of heart failure. Med Chem. 2017;60:5146–5161.
   Web of Science ®Google Scholar
• Neeheim T, How OJ, Myrmed T. The effect of riociguat on cardiovascular function and efficiency in healthy juvenile pigs. Physiol Rep. 2020;8:e14562.
   PubMed Web of Science ®Google Scholar
• Ignarro LG, Furchgott RF, Murad F. Nobel prize in medicine 1998 for work on nitric oxide. BMJ. 1998;317:1031.
   PubMedGoogle Scholar
• Umar S, Van Der Laarse A. Nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010;333:191–201.
   PubMed Web of Science ®Google Scholar
• Brockunier L, Stelmach J, Guo J, et al. Soluble guanylate cyclase stimulators for the treatment of hypertension: discovery of MK-2947. Bioorg Med Chem Lett. 2020;30(21):127574. .
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Wakefield JD, Wilson PJ, et al. A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects. Clin Pharmacol Drug Devel. 2019;8:564–575. .
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Seferovic JP, Wakefield JD, et al. An exploratory, randomized, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Dabetologia. 2020;63:733–743.
   PubMed Web of Science ®Google Scholar
• Frey R, Muck W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator, BAY 63-2521: an ascending –dose study in healthy male volunteers. J Clin Pharmacol. 2008;48:926–934.
   PubMed Web of Science ®Google Scholar
• Shea CM, Price GM, Liu G, et al. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and organ damage in the Dahl model of cardiorenal failure. Am J Physiol Renal Physiol. 2020;318:F148–F159.
   PubMed Web of Science ®Google Scholar
• Tobin JV, Zimmer DP, Shea CM, et al. Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, antiinflammatory, and antifibrotic effects in preclinical models of disease. J Pharmacol Exp Ther. 2018;365:664–675.
   PubMed Web of Science ®Google Scholar
• Sharovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28:166–1675.
   Web of Science ®Google Scholar
• Geschka S, Kretschmer A, Sharkbvska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. Plos One. 2011;6(7):e21853. .
   PubMed Web of Science ®Google Scholar
• Zanfolin M, Faro R, Araujo EG, et al. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. Cardiovasc Pharmacol. 2006;47:391–395.
   PubMed Web of Science ®Google Scholar
• Benza RL, Farber HW, Frost A, et al. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: impact of changes in risk score on survival. J Heart Lung Transplant. 2018;37(4):513–519. .
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Gomez-Sanchez MA, Humbert M, et al. Riociguat treatment In patients with chronic thromboembolic pulmonary hypertension: final safety data from the EXPERT registry. Resp Med. 2020;178:106220.
   PubMed Web of Science ®Google Scholar
• Murata M, Kawakami T, Kataoka M, et al. Clinical significance of guanylate cyclase stimulator, riociguat, on right ventricular functional improvement in patients with pulmonary hypertension. Cardiology. 2021;146(1):130–136. .
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomization trial. JAMA. 2015;314(21):2251–2262. .
   PubMed Web of Science ®Google Scholar
• Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–1127. .
   PubMed Web of Science ®Google Scholar
• Ullah W, Mukhtar M, Al-Mukhtar A, et al. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis. World Journal of Cardiology. 2020;12(10):501–512. .
   PubMed Web of Science ®Google Scholar
• Park M, Sandner P, Krieg T. cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Res Cardiol. 2018;113(4):24.
   PubMed Web of Science ®Google Scholar
• Leineweber K, Moosmang S, Paulson D. Genetics of NO deficiency. Am J Cardiol. 2017;120(Suppl):S80–S88.
   PubMedGoogle Scholar
• Emdin CA, Khera AV, Klarin D, et al. Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling. Circulation. 2018;137(3):222–232. .
   PubMed Web of Science ®Google Scholar
• Saleh S, Frey R, Becker C, et al. Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food. Pulm Circ. 2016;6(S1):S66–S74. .
   PubMedGoogle Scholar
• Boettcher M, Thomas D, Mueck W, et al. Safety, Pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2020;77(4):527–537. .
   PubMed Web of Science ®Google Scholar
• Thoomen R, Sips P, Bloch KD, et al. Pathophysiology of hypertension in the absence of Nitric Oxide/cyclic GMP signaling. Curr Hypertens Rep. 2013;15:47–58.
   PubMed Web of Science ®Google Scholar
• Toppanen H, Ponilkowski P. sGC stimulators and activators. Intern Forum J. 2019;18:2–6.
   Google Scholar
• Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat: a soluble guanylate cyclase activator: results from the randomized. Controlled, phase IIb COMPOSE programme in acute decompensated heart failure syndromes. Eur Heart J. 2012;14:1056–1066.
   Web of Science ®Google Scholar